Ice Miller Partner Speaks About Mergers and Acquisitions Activity

Tuesday, January 25, 2011 by Janice Wilken
HumkeIce Miller partner Steve Humke was quoted in the Indianapolis Business Journal article, "Uptick in M&A Activity Suggests a Turnaround," on January 24 for the publication's "Big Deals" issue.

2010 Results

Monday, June 14, 2010 by Joy Fischer

Study highlights from 2010 include the following

•  Corporate reputation is back on top as the highest ranked business issue. In 2009 the highest ranked issue was customer loyalty and retention.
•  Cost of living is still seen as the strongest advantage that Indiana has over neighboring states and has been on the rise as the strongest advantage since 2007.
•  CEOs appear optimistic about 2010. There is a stronger likelihood they will pursue adding jobs, green development, outsourcing, mergers and acquisitions, new alliances, and a variety of other forward looking or growth oriented activities, when compared to 2009.
•  CEOs continue to remain positive about Indiana’s ability to attract business to the state.
•  Perceptions regarding the strength of education programs in the areas of advanced manufacturing and alternative energy have increased since 2009.
•  CEOs report that workers lowest in demand are manufacturing, non-skilled and bio-tech/life science workers.

View the 2010 CEO Survey Full Report.

View the 2010 CEO Survey Excutive Summary.

Financial Reform Legislation: Will it Limit Private Equity?

Wednesday, May 26, 2010 by Janice Wilken

In the wake of the recent financial crisis, on May 20, 2010, the U.S. Senate voted to adopt sweeping financial reform.  The proposed Restoring American Financial Stability Act of 2010 would:

• create a number of new governmental bodies designed to protect investors;
• severely limit government bail-outs;
• streamline bank regulation;
• regulate trading of derivatives;
• increase regulation of hedge funds and credit rating agencies;
• affect executive compensation;
• undertake some reform of the SEC;
• strengthen the Federal Reserve; and
• increase regulation of securitization and municipal securities transactions. 

But, could it also affect the availability of private equity funds?

The bill aims to end so-called "too big to fail" bail-outs.  The Volcker Rule is part of that effort.  The rule prohibits banks and their affiliates from investing in or sponsoring hedge funds and private equity funds and otherwise requires limited relationships with hedge funds and private equity funds.  Non-bank financial institutions supervised by the Federal Reserve will also have restrictions on their hedge fund and private equity investments. 

Banks and other regulated financial institutions provide a significant portion of the capital for private equity funds.  Without that capital, private equity funds will likely be smaller and less inclined to make investments.  In many instances, private equity dollars are available to companies seeking funding in circumstances under which traditional banks would not lend.  In those cases, the limited availability of private equity dollars could damage companies seeking funding.  Those companies may not be able to obtain funds for operations, strategic acquisitions or expansion if private equity money is not available.

While the financial reform bill has many legitimate purposes, it may have consequences that were not anticipated by the drafters.  Those consequences will affect not only private equity funds themselves but also companies that rely on private equity as a source of funding.

Private Equity Exit Strategies

Thursday, October 15, 2009 by Janice Wilken

A recent edition of PitchBook News Private Equity: Basic Edition cited a decrease in 2009 in exits from private equity investments through sales to other private equity firms.  The article stated that these secondary sales are down approximately 22 percent from their levels in 2005 through 2007.  In 2008, many private equity exits took the form of sales to strategic buyers.  In 2009, IPOs increased by approximately 19 percent, according to the article. 

So what does this mean?  Late 2007 saw the beginning of the current economic crisis and, in that time, it appears that private equity firms continued to feel confident in investing their money.  In many cases, they did so by buying out other private equity firms. 

In 2008, when it became clear that the economic crisis would not be short-lived or minor, strategic buyers became the most obvious source for private equity liquidity.  Strategic buyers saw opportunities to enhance their businesses through the synergies offered by private equity portfolio companies.  In addition, valuations were very low:  the perfect formula for strategic acquisitions.

In the later parts of 2009, we have seen the public equity markets bounce back significantly.  Instead of shying away from the public markets' previously unequaled volatility and sharp decreases in value, private equity firms looking for an exit option seem to have again turned their focus to the IPO as a possible exit strategy. 

Hopefully, markets will continue to stabilize, valuations will become more reliable and private equity firms will invest some of the money they are currently holding.  If all these things happen, we can hope to see a return of multiple options for private equity exit strategies.
 

The Private Equity Overhang

Monday, July 6, 2009 by Janice Wilken

The Alliance of Mergers & Acquisitions Advisors and PitchBook Data recently released a study of the private equity industry.  The study showed that there is an overhang of approximately $400 billion in private equity fundraising.  That means private equity firms have raised about $400 billion more than they have invested.  There's a lot of money out there waiting to be invested.  In fact, it's at an all-time high.  Click here to see a copy of the report.

As tough as times have been, people have continued to give their money to private equity funds.  The funds just haven't found companies that they consider good investments.  So what needs to happen?  According to some, it's a matter of companies lowering their expectations.  Companies can no longer expect to get the kind of multiples or the kind of leverage that were used before 2007.  Others say it's all about the stability of the economy and the re-opening of the credit markets.  Still others say that investors need to change the way they do diligence on a company.  The old methods will no longer work in light of the current economic realities.

So which is it?  Probably a combination of all.  Either way, I look forward to the days when we start to use that $400 billion.

I'm Trying to Sell My Company. What Can I Expect in This Market?

Thursday, July 2, 2009 by Janice Wilken

The world of mergers and acquisitions looks a lot different than it did just two years ago.  When credit was easily available to a buyer financing an acquisition, things were easier for sellers.  Now, buyers are looking to sellers to take on more of the risk.

  • Promissory notes.  Many buyers are asking sellers to accept part (or even all) of the purchase price as a note.  In other words, the seller gets less cash at closing and only receives payments under the note if the company is able to pay.
  • Earn-outs.  An earn-out is a mechanism where a seller receives part of the purchase price over time, depending on how well the business is performing.  Usually, the buyer and seller will agree upon financial measurements that the company has to meet in order for the seller to receive any payment.  Earn-outs can be very complicated and difficult to track and measure after the closing.
  • Mezzanine financing.  Because senior debt is not as readily available as it once was, buyers are turning to mezzanine lenders.    Mezzanine capital is generally subordinated to any senior debt but has priority over common equity.  Mezzanine financing generally has a higher interest rate than senior debt.  That may cause the buyer to provide less generous financial terms to the seller.
  • Equity rollovers.  The buyer may ask the seller to roll over some of its equity into the new company.  That is, rather than receiving the purchase price that would be attributable to all of the seller's interest in the company, it will receive only a portion of the full purchase price plus some equity interest in the new company.  In an equity rollover, the seller continues to own a portion of the business and bears the risks related to that ownership.

I'm Thinking About Using Venture Capital to Raise Money for My Company. What will a Venture Capital Firm Expect?

Friday, May 1, 2009 by Janice Wilken

Venture capital firms generally demand a number of rights to protect their investments.

Venture capitalists usually receive shares of preferred stock when they invest in a company, while the founders and other initial investors hold common stock.  Of course, if you raise successive rounds from venture capital firms, you will likely end up with several different series of preferred stock with different rights and preferences.  Preferred stock has certain advantages over common stock, particularly dividend and liquidation preferences.  This means that if the company decides to distribute dividends to its stockholders, or sell its assets and distribute the proceeds to its stockholders, the holders of preferred stock will have priority over the common stockholders.  They will be entitled to receive some portion (or even all) of the dividend or sale proceeds before any of the common stockholders receive any money at all.

Preferred stock will probably have better voting rights as compared to common stock.  For example, the company will have to get approval from the holders of a certain percentage of the preferred shares to take major corporate actions, such as approval of the annual budget, amendment of articles or bylaws, liquidation of the company, creation of a new class of securities with rights equal to or better than the preferred stock, sale of the company or acquisition of another company.  This structure lets the venture capital firm have a say in decisions that will have a large impact on the company.

The venture capital firm will also likely demand representation on the company's board of directors.  The number of members will vary depending on the current structure of the company and the amount of capital invested by the venture capitalists, but at least one, and often more than one, spot on the board will probably be reserved for members elected or appointed by the venture capital firm.

Also, venture capital investors will want information and reports about the company so it can track its investment.  For example, the company will likely have to deliver its quarterly and annual unaudited financial statements.  Many venture capital firms will demand audited financial statements, which can be a significant expense for the company.  Plus, venture capital investors will expect some other rights, such as the right to force the company to register its common shares with the Securities and Exchange Commission under some circumstances or to participate in any registration initiated by the company (registration rights), the option to purchase shares of stock of the company that other stockholders want to sell (right of first refusal), the right to purchase any new shares issued by the company (preemptive rights) and an adjustment of the conversion to common stock price in the event the company sells stock at a lower valuation (anti-dilution protection).

Looking at all of the ownership and control pieces likely to be obtained by a venture firm, it will probably end up exercising a lot of control over the company.  Such is the price of venture capital.  However a venture capital firm will probably allow the day-to-day operations of the company to continue to be handled by the business people.

How Do I Value My Company as I Try to Raise Money?

Friday, March 27, 2009 by Janice Wilken

Most business owners eventually deal with the issue of their company's worth, whether in establishing a strike price for options or in trying to sell or raise money for their companies. Stating the obvious, the value is what a willing buyer would be willing to pay and a willing seller would accept. That said, business owners are often understandably frustrated when they see the lack of objectivity in determining the value of their business. Unfortunately, like valuing baseball cards, valuing a business is less of a science than an art.

This is not to say that valuations do not have mathematical explanations, nor that there are not industry starting points (as discussed below), but all of that is academic without a willing buyer or investor making a real offer. Using the right advisors, particularly valuations experts, can add to your bargaining leverage, ground negotiations on both sides, offer a variety of creative methods and financing options, and introduce new potential investors.

There are several well-accepted methods of valuing a company in both an investment and a capital raise context. Buyers and investors often use one of the following valuation methodologies: (i) a negotiated multiple of EBITDA (earnings before interest, taxes, depreciation and amortization); (ii) a discounted cash flow analysis (which is often used in the leveraged buy-out setting where acquisition debt payments need to be covered from free cash flows); and (iii) market comparables (where comparable businesses are identified and their stated valuations are used as a basis, and differentiating your business may be the primary point of negotiation). A good valuation expert can help identify other valuation methods that would be most favorable to your company.

The different methodologies rarely have the same outcome. The above methods are all attempts to create some kind of baseline which can be useful to both buyers or investors and sellers.

I Need to Prepare a Private Placement Memorandum in Connection with My Fundraising Efforts for My Company. What is Involved?

Friday, March 27, 2009 by Janice Wilken

When you are raising money for your company, a private placement memorandum (PPM) can be used to provide information to potential investors to help them evaluate the merits of an investment in your company.  It is intended to disclose material information to potential investors about the securities you are selling, your company and its business, in particular, the risk factors associated with an investment in your company.  A PPM is not always required for full legal compliance with securities regulations, but it is a useful way to show that you provided all material information to investors.  Generally, each PPM will include a business plan, risk factors, a description of how you intend to use the proceeds of the offering, a capitalization table and a description of the closing process for the investment.

However, there is no "one size fits all" PPM.  They will vary according to the company's size, industry, development stage, offering size and other factors.  Therefore, it is important that a company offering securities retain competent legal counsel to assist with preparing the PPM and conducting the offering.

Business Plan

The business plan section lets you educate potential investors about your company's strengths and weaknesses.  This section should describe the products and services offered by your company, the needs of the market place, the risks which may be posed by actual and potential competitors, your strategic plans with respect to innovation, marketing and financing, and the overall business environment in which your company will operate during the term of the investment.  In most cases, the business plan section is drafted by you and reviewed by legal counsel.  One of the major purposes of legal counsel's review is to ensure that the PPM, taken as a whole, is not misleading to potential investors.

Risk Factors

The risk factors section of the PPM is a specific description of some of the risks that may be associated with your company, the industry and the particular terms of the offering.  If well drafted, the risk factors section can provide useful protection against some potential claims by investors.  Although the actual risk factors for your company will depend on your company's specific business and activities, there are some fairly standard disclosures found in most PPMs.  For example, a "development stage" company will likely include in its PPM the following as risk factors:  lack of revenue, losses and financing requirements, product development risks, technological risks, manufacturing and distribution risks, dependence on key employees, competition, regulatory risks, potential inability to exercise a redemption right, dilution, no market for shares, and difficulty of determining an appropriate offering price.  The company should also include any other risks relevant to its particular business.

Use of Proceeds

The PPM should include a section that describes how you intend to use the proceeds of the offering.  Naturally, you will want to retain some flexibility regarding the use of the funds, but the investors will likely require at least a general breakdown of uses.  The use of proceeds section might list product development, acquisition of new technologies, facilities expansion, hiring of new employees or general working capital requirements as possible applications of the proceeds.  The key to this section is to strike the delicate balance between flexibility for your company and certainty for the investor.

Capitalization

The capitalization section describes the capital structure of your company.  The capitalization section should include a capitalization table which will allow a potential investor to determine how much of the company he will own (or how much of the company's debt he will own).  The capitalization table should reflect both the actual debt and shareholders' equity of the company prior to the offering, as well as the adjusted figures reflecting the completion of the offering on the terms contemplated in the PPM.

Closing Process

The closing process or subscription procedure (as some refer to it) can be foreign and confusing for investors.  Therefore, it is helpful to provide investors some guidance in the PPM regarding how the closing will proceed.  You can require that a minimum amount of money be raised before you will proceed with the offering.  If that is the case, the PPM should disclose the minimum aggregate capital commitments. After any applicable minimum is met, qualified investors generally have to complete and return a subscription agreement which obligates them to buy the securities, along with a check for the amount of the purchase price (payment may also be made by wire transfer), by a date specified in the subscription agreement.  Sometimes the subscription agreement is included with the PPM.

The investor may also be required to complete and return an "accredited investor" questionnaire to allow the company to comply with certain exemptions from the securities laws.  If required, the questionnaire is typically attached to the subscription agreement. 

After the company has received all signed documentation and funds, it should provide the investor signed counterparts of the documentation.  The company may also provide the investor share or unit certificates or promissory notes, if applicable, and signed copies of the company's governing documents.  If the company is making the private offering pursuant to certain registration exemptions, after the closing it may need to file various documents, including Form Ds and U-2 Uniform Consents to Service of Process, with the state and federal authorities where the investors are located.

Education

Friday, February 27, 2009 by Joy Fischer

President Obama has made education a key component of the stimulus package.  More than $43 billion has been allocated to the Department of Education and an additional $9.9 billion in tax credit bonds for the land acquisition for, or construction, rehabilitation or repair of public school facilities.

Read more about the impact on education.
 

September's Distinguished Speaker Series -- Comments by Jennifer Rhodes

Friday, October 3, 2008 by Harry Gonso
Jennifer Rhodes is a partner in Ice Miller's Private Equity/Venture Services Practice.  Her primary area of concentration is in private equity fund formation and operations, venture capital and private equity financings, mergers and acquisitions, and general corporate matters.

In our third in a series of life science distinguished speakers luncheons we were honored to have Dr. Ora Hirsch Pescovitz the Executive Associate Dean for Research and Edwin Letzter Professor of Pediatrics at Indiana University School of Medicine. She served as director of Pediatric Endocrinology and Diabetology at Indiana University School of Medicine from 1990-2004. In September 2004, she was named to the position of CEO and President of Riley Children's Hospital. In her role in the Dean's office, she oversees all research at the School of Medicine

Dr. Pescovitz asked the question why do life science research in Indiana? And the answer lies within the state’s national ranking for five major health indicators in Indiana: cancer deaths, smoking prevalence, obesity, cardiovascular deaths, and diabetes.  The state ranks in the bottom half of each of these health indicators, and in the bottom 10 of all states in most cases. 

Not only the health impact, but the economic impact is another reason for the state to focus on the life science industry.  Dr. Pescovitz mentioned that high-tech research driven industries have contributed to over a third of the nation's economic growth over the past decade and the U.S. biotech industry had revenues of over $65 billion in 2007, which is up 11% nationally over 2006, so why shouldn't Indiana be getting a piece of that important pie? 

Dr. Pescovitz also discussed how Indiana University School of Medicine is driving the life sciences initiative in Indiana and provided examples of new Indiana businesses, such as Fast Diagnostics, CS Keys, EndGenitor and Immuneworks, not only expanding the technology and research but also bringing in new forms of revenue to the State.  She pointed out that success in the life sciences industry requires a significant amount of collaboration. 

The Indiana Clinical and Translation Scientists Institute is a statewide partnership to transform life science research and health care delivery.  The goals of this project are largely to use basic discoveries and translational approaches to new scientific discoveries from the bench to the bed-side and then to translate these discoveries from the bed-side and move them into the community and from the community into actual medical practice and then taking that feedback from the community back to the researchers so it really is a full cycle. 

Dr. Pescovitz closed by commenting that the cost of life science research is high, but the  return on investment is priceless.

Distinguished Speaker Series -- Comments by Jennifer Rhodes

Friday, May 16, 2008 by Harry Gonso
Jennifer Rhodes is a partner in Ice Miller's Private Equity/Venture Services Practice.  Her primary area of concentration is in private equity fund formation and operations, venture capital and private equity financings, mergers and acquisitions, and general corporate matters.

On April 25, 2008, Ice Miller hosted Dr. Mervin Yoder, with the Indiana University School of Medicine, for a presentation on umbilical cord research and stem cells.  Dr. Yoder is a professor of pediatrics focusing his research efforts on stem cell transplantation.  He also serves on the Board of Directors of EndGenitor Technologies and is the medical director for The Genesis Bank in Indianapolis.

 

At the conclusion of Dr. Yoder's remarks, one of the participants asked about the venture capital opportunities for commercialization of stem cell research.  According to Dr. Yoder the outlook is promising, especially in light of recent legislation at the Indiana statehouse that established a public umbilical cord blood bank in Indiana.  The end goal is to be able to collect, screen and maintain as many samples, or units as possible.  These units can then be used for treatment or, if deemed inappropriate for transplantation, they can be used for further research.

 

Dr. Yoder spoke specifically about his work with two promising life science companies:  EndGenitor Technologies and The Genesis Bank.  Founded in 2004, The Genesis Bank serves as a cord blood bank and was founded by physicians and scientists specializing in cord blood therapies, neonatal medicine, and cell and tissue preservation. Currently The Genesis Bank has banked over 4,000 cord blood samples.

 

EndGenitor Technologies' mission is to isolate, expand and commercialize novel umbilical cord blood stem cells for the emerging field of self-therapeutics.  EndGenitor has licensed (from Indiana University Research & Technology Corporation) technology relating to proprietary, novel, and highly proliferative stem cell populations that mature into the lining of new blood vessels.

 

Both of these companies are examples of life science start-ups, headquartered in Indiana, that are focused on therapies and research relating to stem cells. 

 

Dr. Yoder described stem cells as, "an incredible biological resource."  As more and more companies look to fund stem cell research, and as the research is commercialized and brought to market, we can expect to see new promising treatment options for a variety of blood diseases.

Don’t Overlook Federal Tax Credits When Greening Brown Buildings

Friday, May 2, 2008 by Kristina Tridico
Paul Jones, an associate at Ice Miller, wrote this recently posted blog.  I thought it merited posting here.

----------------------------------------------------------------------------------------------------------------------

“Retention and reuse of older buildings is an effective tool for the responsible, sustainable stewardship of environmental resources,” stated Richard Moe, President, National Trust for Historic Preservation: at a dinner last December where Moe was honored by the National Building Museum with the Vincent Scully Prize for his work on historic preservation.  Moe went on to state that “[N]o matter how much green technology is employed in its design and construction, any new building represents a new impact on the environment.  The bottom line is that the greenest building is one that already exists.”

 

Moe is not alone in seeing the critical interplay between historic preservation and sustainable development.  I’m with him, which is why when I was recently asked by the Indiana Chapter of the United States Green  Building Council to speak to its members and guests about tax incentives for sustainable development I could not resist the opportunity to talk a little bit about federal historic rehabilitation tax credits.  Federal income tax law has allowed for many years two credits , a 10% credit for pre-1936, non-certified historic structures, and a 20% credit for “certified historic structures”.  The credit amount equals credit rate (10% or 20%) multiplied by amount of “qualified rehabilitation expenditures”. 

 

The 20% credit provides the historic developer a source of funds with which to fund gaps in financing.  The source is tax credit equity provided by an investor or investors willing to become an owner of the project for 5 years in return for tax credits generated by the project expenditures.  For example, assuming the project has $10M of qualified rehab expenditures (defined below), the project owner (a partnership for federal tax purposes) has $2M in federal tax credits to pass through to its owners.  The project owners can typically raise 85-95% of the $2M in the form of tax credit investor equity. 

 

There are four basic requirements to consider, though other requirements and limitations(such as those related to tax-exempt use of the property) may apply

 

Must involve a “certified historic structure” 

  • Building is listed in the National Register of Historic Places maintained by the Dept. of Interior pursuant to the National Historic Preservation Act of 1966; or
  • Building is located in a “registered historic district” and certified by the Secretary of the Dept. of Interior as being of historic significance to the district

Must result in “qualified rehabilitated building” 

  • Must be a “building” (apartments, factories, office buildings, warehouses, barns, garages NOT bridges, boats, trains, storage tanks, kilns, ovens)
  • Building must be “substantially rehabilitated”

Must have “qualified rehabilitation expenditures” 

  • Costs associated with renovation, restoration or reconstruction which are chargeable to the capital account for property which is depreciable (Hard construction costs, Walls, floors, ceilings, Windows and doors, Plumbing, electrical, lighting, Construction period interest, taxes and insurance, Architectural and engineering fees, Legal fees related to construction, Reasonable developer fees, Historic consultant fees
  • Certain costs NOT included (Building acquisition costs, Enlargements and new additions, Landscaping, parking lots, sidewalks, Outside environmental cleanup, Building demolition costs, Appliances, Furniture and other personal property, Cabinets and carpet (unless permanently affixed), Feasibility and marketing costs

Must be a “certified rehabilitation” 

  • Rehabilitation of a certified historic structure must be certified by the Secretary of the Dept. of Interior in order to qualify for the credit
  • Three part application process involving the State Historic Preservation Officer (SHPO) and the Dept. of Interior

As mentioned above, other limitations and special rules apply, but historic rehabilitation tax credits can serve as one of the many incentives potentially available to finance sustainable development.

Distinguished Speaker Series -- Comments by Jennifer Rhodes

Tuesday, March 11, 2008 by Harry Gonso

Jennifer Rhodes is a partner in Ice Miller's Private Equity/Venture Services Practice.  Her primary area of concentration is in private equity fund formation and operations, venture capital and private equity financings, mergers and acquisitions, and general corporate matters.

 Dr. Homer L. Pearce's remarks during Ice Miller's recent life science distinguished speaker's series highlight the importance of sufficient research funding for success in the war on cancer.  Research and development costs associated with identifying pharmaceutical solutions are particularly daunting and, given the time to market and current patent protection periods, sometimes commercially unjustifiable.

As a result of the targeted efforts of many, including the Indiana Economic Development Corporation and BioCrossroads, among others, Indiana's unique contribution to the national life science sector is becoming increasingly recognized - not only in terms of its many research institutions, major pharma companies and contract service providers, but also with respect to availability of funding.  In 2006, according to PricewaterhouseCoopers, Indiana ranked 21st in the nation for venture capital investments in the life science sector.

 

According to the S&P-2006, Purdue and Indiana University currently have $200 million in academic life science funding commitments and graduate 10,000 science and engineering students each year.  Both institutions are developing innovative diagnostic equipment and pharmaceutical protocols that, with appropriate funding, can bring life saving treatments to market.  The financial needs of Indiana's innovators have not gone unnoticed by public and private financial sources that are positioned to fund such developments. 

 

In 2008, we should expect to see further growth in Indiana's life science community as our state's leading research scientists build on the efforts of past scientific contributors to develop cutting-edge technologies and as funding sources become increasingly available both locally and nationally.